Immunome's First NDA Decision Looms Over What Comes After Varegacestat

Immunome Inc (IMNM) is scheduled to report second-quarter 2026 earnings on August 5, 2026, with analysts expecting the clinical-stage biopharmaceutical company to post a loss of $-0.51 per share. The report comes as IMNM trades near its highest levels in over a year, up more than 90% over the past 12 months, while investors weigh the company's progress in developing targeted cancer therapies against its continued cash burn and path to profitability.

Part 1: Earnings Preview

Immunome Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody therapies for oncology and infectious diseases, utilizing its proprietary human memory B cell platform to identify novel therapeutic candidates. The company's pipeline includes multiple programs targeting various cancer indications, with investors closely monitoring clinical trial progress and partnership opportunities.

For the second quarter of 2026, analysts expect IMNM to report a loss of $-0.51 per share on August 5, 2026. The company most recently reported first-quarter 2026 results with an actual loss of $-0.48 per share, beating estimates by 20%. Compared to the same quarter last year (Q2 2025), when IMNM posted a loss of $-0.50 per share, the current consensus represents a 2% deterioration in losses year-over-year, though analysts have revised estimates upward from a prior expectation of $-0.50.

Three key themes define this earnings story:

Clinical Pipeline Progress: Investors will scrutinize updates on IMNM's lead programs, particularly any data readouts or enrollment milestones from ongoing trials. The company's ability to advance its antibody candidates through clinical development remains the primary value driver, with any positive efficacy or safety signals likely to impact the stock significantly.

Cash Runway and Burn Rate: With the company posting losses exceeding $2 per share annually, the quarterly cash burn rate and remaining runway are critical metrics. Analysts will focus on whether IMNM can extend its cash position through partnerships, non-dilutive financing, or improved operational efficiency without requiring additional equity raises that could dilute shareholders.

Partnership and Commercialization Strategy: Any announcements regarding strategic collaborations, licensing deals, or plans for eventual commercialization will be closely watched. The company's ability to monetize its platform technology through partnerships could provide validation and non-dilutive funding to support operations.

Analyst commentary ahead of the release reflects cautious optimism, with 14 of 15 analysts rating the stock a Strong Buy. The consensus price target of $35.77 implies substantial upside from current levels, suggesting analysts believe the company's clinical progress justifies the current valuation despite ongoing losses. Recent estimate revisions have been modestly positive, with the Q2 consensus improving from $-0.50 to $-0.51, while full-year 2026 estimates have improved from $-2.43 to $-2.06.

Part 2: Historical Earnings Performance

Immunome has demonstrated a mixed but recently improving track record on earnings performance. Over the past four quarters, the company has delivered two beats and two misses against analyst estimates, with the magnitude of surprises varying significantly.

The most recent quarter (Q1 2026) marked a strong performance, with IMNM beating estimates by 20% ($-0.48 actual vs. $-0.60 expected). This followed two consecutive misses in Q4 2025 (missed by 15.38%) and Q3 2025 (missed by 14.04%). The Q2 2025 result showed a modest beat of 3.85%.

The pattern suggests improving execution in recent quarters, with the company potentially gaining better control over its expense base or benefiting from revenue timing. The dramatic swing from double-digit misses in Q3 and Q4 2025 to a 20% beat in Q1 2026 indicates either more conservative analyst modeling or genuine operational improvement. Investors should note that all reported figures remain deeply negative, reflecting IMNM's pre-revenue clinical stage, so "beats" represent smaller-than-expected losses rather than profitability improvements.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Immunome typically reports earnings before market open, meaning Day 0 captures the initial market reaction during the first trading session after results are released, while Day +1 reflects follow-through momentum.

Historical price action around earnings shows moderate volatility with an average absolute Day 0 move of 3.41% and Day +1 move of 3.30%. The stock has exhibited a slight negative bias on earnings days, though reactions have been mixed across the eight most recent reports.

The most volatile reaction occurred in November 2024, when IMNM dropped 7.21% on Day 0 following results. Conversely, the stock posted its strongest positive reaction in May 2025 with a 6.43% Day 0 gain. The Day +1 ranges have been notably wider, averaging 7.42%, suggesting continued volatility as investors digest the full implications of results and management commentary. The most recent earnings (May 2026) saw a modest 1.35% decline on Day 0 despite the 20% earnings beat, followed by a 2.16% drop on Day +1, indicating that positive earnings surprises don't automatically translate to stock gains for this clinical-stage name.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.78% for the August 21 expiration, which is notably higher than the average historical Day 0 move of 3.41% but below the average Day +1 range of 7.42%. This suggests options traders are anticipating above-average volatility for this earnings release, potentially reflecting heightened uncertainty around clinical updates or cash position disclosures.

Part 3: What Analysts Are Saying

Analyst sentiment on Immunome remains overwhelmingly bullish heading into the Q2 report. The current consensus shows 14 Strong Buy ratings and 1 Hold rating among 15 analysts covering the stock, producing an average recommendation of 4.87 out of 5.0 — near the top of the rating scale. The average price target of $35.77 represents 42.6% upside from the current price of $25.08, with estimates ranging from a low of $30.00 to a high of $40.00.

The analyst consensus has remained unchanged over the past month, with the same 14-0-1 Strong Buy-Hold-Sell breakdown persisting. This stability suggests analysts are maintaining conviction in their bullish thesis despite the stock's strong recent performance. The tight clustering of price targets (all between $30 and $40) indicates broad agreement on valuation, with even the most conservative analyst projecting nearly 20% upside.

The near-unanimous Strong Buy rating is particularly notable for a clinical-stage biotech with no meaningful revenue and ongoing losses exceeding $2 per share annually. This reflects analyst confidence that IMNM's pipeline value and platform technology justify the current $2.6 billion market capitalization, with the potential for significant appreciation as clinical catalysts materialize.

Part 4: Technical Picture

Immunome enters earnings with strong technical momentum and a bullish setup across multiple timeframes. The Barchart Technical Opinion currently stands at 72% Buy, unchanged from last week but significantly improved from 24% Buy one month ago, reflecting a substantial strengthening in technical conditions over the past several weeks.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (Hold): Neutral reading suggests some consolidation in the intermediate timeframe, providing a potential base for the next move
• Long-term (100% Buy): Maximum bullish signal confirms the stock is in a strong uptrend on longer timeframes, consistent with the 92% gain over the past year

Trend Characteristics: The trend is characterized as Average strength but Strengthening, suggesting momentum is building and the technical environment is becoming increasingly supportive.

The stock is trading at $25.08, positioned above all major moving averages — the 5-day ($23.41), 10-day ($22.99), 20-day ($22.96), 50-day ($21.32), 100-day ($21.66), and 200-day ($21.05). This complete alignment with price above all moving averages is a classically bullish configuration, indicating strong trend support across all timeframes. The stock is trading approximately 19% above its 200-day moving average, confirming the strength of the longer-term uptrend.

Key technical support now sits at the 20-day moving average around $22.96, with the 50-day at $21.32 providing secondary support. The stock is approaching but still 9.3% below its 52-week high of $27.65 set in February 2026, suggesting room to run if earnings catalyze further upside. With the RSI at 50.42 (neutral territory) and the stock above all moving averages while maintaining 100% Buy signals in both short and long-term timeframes, the technical setup is decidedly supportive heading into the earnings release. However, the elevated implied volatility of 108.83% and the 6.78% expected move suggest traders should prepare for significant post-earnings price action in either direction.